產(chǎn)品[
TT 人甲狀腺導管癌細胞
]資料
如果您對該產(chǎn)品感興趣的話(huà),可以
產(chǎn)品名稱(chēng):
TT 人甲狀腺導管癌細胞
產(chǎn)品型號:
CRL-1803
產(chǎn)品廠(chǎng)商:
美國標準生物品收藏中心（ATCC）
產(chǎn)品文檔:
無(wú)相關(guān)文檔
簡(jiǎn)單介紹
CRL-1803 TT 人甲狀腺導管癌細胞， ATCC 細胞|細胞系|細胞株|腫瘤細胞|細胞|貼壁細胞|懸浮細胞；細胞庫管理規范，提供的細胞株背景清楚，提供參考文獻和培養條件！
TT 人甲狀腺導管癌細胞
的詳細介紹
CRL-1803 TT 人甲狀腺導管癌細胞
|
|
CRL-1803?
|
|
|
|
|
TT
|
|
|
SS Leong
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent
|
|
|
Homo sapiens (human)
|
|
|
epithelial
|
|
|
Organ: thyroid
Tissue: medulla
Disease: carcinoma
|
|
|
calcitonin; carcinoembryonic antigen (CEA) [21867]
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Yes
|
|
|
Amelogenin: X
CSF1PO: 10,13
D13S317: 11
D16S539: 12,13
D5S818: 12,13
D7S820: 10,12
THO1: 6,9
TPOX: 8,11
vWA: 16,18
|
|
|
aneuploid with several markers; modal number = 40; range = 32 to 86 [21867]
|
|
|
77 years
|
|
|
female
|
|
|
Caucasian
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated F-12K Medium, Catalog No. 30-2004. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
|
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Twice per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
|
|
|
Culture medium, 95%; DMSO, 5%
|
|
|
83 hrs
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2004
recommended serum:ATCC 30-2020
|
|
|
21867: . Advances in thyroid neoplasia, 1981. Rome: Field Educational Italia; 1981.
32264: Behr TM, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res. 57: 5309-5319, 1997. PubMed: 9393755
|
|
